Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Pharmacogenomic Testing in Current Clinical Practice -

Pharmacogenomic Testing in Current Clinical Practice

Implementation in the Clinical Laboratory
Buch | Softcover
272 Seiten
2013
Humana Press Inc. (Verlag)
978-1-61779-726-2 (ISBN)
CHF 299,55 inkl. MwSt
  • Versand in 10-15 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
While the basic principles of personalized medicine and pharmacogenomics has been covered by numerous texts, there are none to date that focuses on the specific tests themselves that are in current clinical practice and those that are being proposed for implementation in the near future. Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory focuses almost entirely on the specifics of each test that is needed to implement these tests into a clinical laboratory. This volume presents the first compilation of the tests currently in routine clinical use. The chapter authors of this unique and invaluable title comprise a range of renowned authorities and investigators who have conducted the essential clinical trials necessary to justify pharmacogenomic testing today. The book is divided into four parts: Basic Concepts, Specific Pharmacogenomic Targets, Drugs that Cause Delayed Hypersensitivity, and Miscellaneous Drugs. Each author provides a pharmacologic background on the target drug, the need for pharmacogenomic testing, and how results can be translated into clinical decisions. Where appropriate, case studies are given to illustrate typical clinical scenarios. An extensive bibliography is provided so that the reader can refer to the original studies. This well-designed resource will appeal to clinical laboratory directors who are contemplating or assigned the task of establishing a pharmacogenomics laboratory and a wide range of clinicians who must interpret results of testing. Focused and immensely useful, Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory is a timely and outstanding contribution to the literature and will be instrumental in defining this rapidly growing field.

Part 1.        Basic concepts      

Chapter 1.      Issues in Translation of Pharmacogenomics into Clinical Practice.

                        Kiang-Teck J. Yeo, Nikolina Babic, Alan H.B. Wu

Chapter 2.      Molecular Diagnostic Methods in Pharmacogenomics                        Nikolina Babic*, Loren J. Joseph, Kiang-Teck J. Yeo

Chapter 3.      Economics of pharmacogenomic testing in clinical practice

                        Alan H.B. Wu

Chapter 4.      From Personalized Medicine to Personalized Justice: The Promises of Translational Pharmacogenomics in the Justice System

Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.

 

Part 2.        Specific pharmacogenomic targets: Chemotherapeutics

Chapter 5.      Irinotecan

R. Stephanie Huang, Federico Innocenti and Mark J. Ratain

Chapter 6.      Pharmacogenomics of tamoxifen

Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman

Chapter 7.      Thiopurines

Terreia S. Jones, Mary V. Relling

 

Part 3.       Specific pharmacogenomic targets: Cardiovascular drugs

Chapter 8.      The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs

Charles Eby

Chapter 9.      Clopidogrel and Salicylates

Janice Y Chyou, Marc S Sabatine

Chapter 10.    DNA-Guided Statin Therapy

Gualberto Ruaño, Richard L. Seip, Jorge Duconge

Chapter 11.    The statin response gene: Kif6

....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.

 

Part 4.        Drugs that cause delayed hypersensitivity

Chapter 12.    Abacavir

Elizabeth J. Phillips, Simon A. Mallal

Chapter 13.    Allopurinol

Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen

Chapter 14.    Carbamazepine and its structurally-related antiepiletics

Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen

Part 5........ Miscellaneous drugs

Chapter 15.    Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury

Hong-Kee Lee, Lionel D. Lewis

Chapter 16.    Immunosuppressants Pharmacogenomics

                        Ping Wang

Steven H.Y. Wong, Christopher Happy, Daniel Blinka, Susan Goch, Jeffrey M. Jensen, Joseph M. Donald, Howard Coleman, Saeed A. Jortani, Yolanda Lurie, Cynthia L. Morris-Kukoski, Manuela G. Newman, Paul J. Orsulak, Tara Sander, Michael A. Wagner, Jennifer R. Wynn, Alan H.B. Wu, Kiang-Teck J. Yeo.

 

Part 2.        Specific pharmacogenomic targets: Chemotherapeutics

Chapter 5.      Irinotecan

R. Stephanie Huang, Federico Innocenti and Mark J. Ratain

Chapter 6.      Pharmacogenomics of tamoxifen

Christine LH Snozek, Alicia Algeciras-Schimnich, Matthew P Goetz, Loralie J Langman

Chapter 7.      Thiopurines

Terreia S. Jones, Mary V. Relling

 

Part 3.        Specific pharmacogenomic targets: Cardiovascular drugs

Chapter 8.      The Pharmacogenetics of Vitamin K Antagonist Anticoagulation Drugs

Charles Eby

Chapter 9.      Clopidogrel and Salicylates

Janice Y Chyou, Marc S Sabatine

Chapter 10.    DNA-Guided Statin Therapy

Gualberto Ruaño, Richard L. Seip, Jorge Duconge

Chapter 11.    The statin response gene: Kif6

....................... H. Robert Superko, Tom White, James Forrester, Spencer King III.

 

Part 4.        Drugs that cause delayed hypersensitivity

Chapter12.    Abacavir

Elizabeth J. Phillips, Simon A. Mallal

Chapter 13.    Allopurinol

Pei Chen, Shuen-Iu Hung, Shih-Yang Chen, Yuan-Tsong Chen

Chapter 14.    Carbamazepine and its structurally-related antiepiletics

Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen

Part 5........ Miscellaneous drugs

Chapter 15.    Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury

Hong-Kee Lee, Lionel D. Lewis

Chapter 16.    Immunosuppressants Pharmacogenomics

                        Ping Wang

Chapter 14.    Carbamazepine and its structurally-related antiepiletics

Shuen-Iu Hung, Wen-Hung Chung, Jing-Jane Tsai, Yuan-Tsong Chen

Part 5........ Miscellaneous drugs

Chapter 15.    Pharmacogenetics of Flucloxacillin and Amoxicillin-Clavulanate Associated Hepatic Dysfunction/Injury

Hong-Kee Lee, Lionel D. Lewis

Chapter 16.    Immunosuppressants Pharmacogenomics

                        Ping Wang

Reihe/Serie Molecular and Translational Medicine
Zusatzinfo XVI, 272 p.
Verlagsort Totowa, NJ
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Studium 2. Studienabschnitt (Klinik) Pathologie
Naturwissenschaften Biologie Genetik / Molekularbiologie
Schlagworte Clinical Pharmacogenomics • Irinotecan • Molecular Medicine • Personalized medicine • Tamoxefin • Translational Medicine
ISBN-10 1-61779-726-X / 161779726X
ISBN-13 978-1-61779-726-2 / 9781617797262
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Gerald Höfler; Hans Kreipe; Holger Moch

Buch | Hardcover (2024)
Urban & Fischer in Elsevier (Verlag)
CHF 145,55

von Thomas Kirchner; Hans Konrad Müller-Hermelink …

Buch | Softcover (2023)
Urban & Fischer in Elsevier (Verlag)
CHF 58,75
Klinisch-pathologische Übersichtskarten

von Thomas Cerny; Kirill Karlin

Buch | Hardcover (2023)
Springer (Verlag)
CHF 48,95